Data from Overseas Phase III Trial (LITHE) of "Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Demonstrates Efficacy in Preventing Structural Joint Damage in Rheumatoid Arthritis Patients
Oct 27, 2008
Data from Overseas Phase III Trial (LITHE) of "Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Demonstrates Efficacy in Preventing Structural Joint Damage in Rheumatoid Arthritis Patients
Data from Overseas Phase III Trial (LITHE) of "Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Demonstrates Efficacy in Preventing Structural Joint Damage in Rheumatoid Arthritis Patients
